ArticleFrontiers in oncology2025
The burden of thyroid cancer and its association with national development levels in Asia: evidence from 47 countries (1990-2021).
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ethnic Background as a Determinant of Thyroid Cancer Risk: A Decade-Long National Cohort Study Reveals Divergent Epidemics in Saudi Arabia.Saudi medical journal · 2026Article
- Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells.Current oncology (Toronto, Ont.) · 2025Article
- Identification and functional characterization of hub genes CLTA, EDIL3, HAPLN1, and HIP1 as diagnostic biomarkers and therapeutic targets in thyroid cancer and Hashimoto's thyroiditis.Clinical and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study examines the trends in thyroid cancer incidence and mortality and explores their relationship with national development levels. Methods: Data on thyroid cancer from 47 countries were sourced from the Global Burden of Disease 2021 study, covering the years 1990-2021. National development was measured using the Human Development Index (HDI), Social Progress Imperative (SPI), Nutrition and Medical Care (NMC), the Density of Doctors per 100,000 population (DOD), and Personal Healthcare Spending (PHS). Correlations between these indicators and thyroid cancer burden were analyzed using scatterplot matrices, heat maps, and principal component analysis (PCA). The mortality-to-incidence ratio (MIR) served as a proxy for thyroid cancer survival rates. Results: In 2021, thyroid cancer caused 44,798 deaths globally, up from 21,893 in 1990. Asia accounted for 62.8% of the cases. Among the working-age population, deaths ranged between 10,477 and 27,187, while incidence rates rose from 1.41 per 100,000 in 1990 to 3.36 per 100,000 in 2021. Nine out of the top ten countries in terms of incidence were classified as high or very high in HDI. The incidence of thyroid cancer correlated positively with HDI (Corr = 0.365), SPI (Corr = 0.384), and NMC (Corr = 0.332), particularly among men. Mortality, however, showed a negative correlation with HDI (Corr = -0.401), NMC (Corr = -0.437), and PHS (Corr = -0.446). The global MIR dropped from 0.135 in 1990 to 0.068 in 2021, though Asia saw a 21.1% rise in mortality and a 138% increase in incidence among the working-age population. Conclusion: The rising incidence of thyroid cancer in Asia, particularly in developed nations, has contributed to a global increase, though improved prognoses have led to better survival outcomes over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.